Forum On Financing Biotechs: Partnering

1
Forum On Financing Biotechs Partnering
BC Biotech

• The Biotech Perspective
• May 15, 2002
• Celia Courchene
• VP, Business Development
• Xenon Genetics Inc.

2
Xenon Genetics Background

• Private genomics-based drug discovery/development
  company
• Founded 1996 by Drs. Michael Hayden, Simon
  Pimstone John Kastelein (all clinical
  scientists)
• Based in Vancouver expanded to Montreal through
  the acquisition of RGS Genome in 2000
• Currently 100 FTEs, including 33 MDs,
  MD/PhDs, PhDs
• Raised gt87 M to date, including 74 M in the
  mezzanine round in 2001 (Investors Fidelity,
  Invesco, JP Morgan, Novo Pfizer)
• Experienced Management Team Board

3
Xenon Genetics Strategic Plan
Near Term (2002)

• Integrated drug discovery company
• Develop portfolio of high value drug targets and
  compounds

Mid Term (2003-2004)

• Forward integrate into pre-clinical and clinical
  development
• Advance drug candidates to proof-of-principle in
  human trials

Longer Term(2005)

• Genomics-based pharmaceutical company
• Develop/market new drugs addressing unmet
  clinical needs

4
Xenon Genetics Partnering Experience

• Corporate
• Pfizer
• License ABCA1 gene for the development of small
  molecule therapeutics for elevating
  HDL-cholesterol
• Multi-year research funding
• Academic
• University of Wisconsin
• McGill
• Clinical

5
Xenon Genetics Clinical Collaborations
CANADACVD, CNS
DENMARKCVD, CNS
NETHERLANDSCVD
FRANCECNS
ITALYMetabolic
TURKEYMetabolic
LEBANONCNS
BRAZILCNS
ARGENTINACNS
TUNISIACNS
SOUTH AFRICAMetabolic
24 collaborations covering 35 distinct and
informative populations
6
Biotech Partnering Objectives

• Infancy
• Access Technology (in-licensing)
• Academic institutions
• Mid Life
• Exploit Own Technology (out-licensing)
• Third Party Validation
• Pharma
• Wall / Bay Street
• Assist with financings
• Close private rounds
• Go public
• Cash for operations
• Build Infrastructure
• Access External Expertise
• Development Marketing
• Access Capabilities
• CROs
• Mature
• Build Pipeline (in-licensing)

7
Biotech Partnering Deal Structures

• Partnering structures can include
• Research collaborations
• In licenses
• Out licenses
• Options
• CRO Agreements
• JVs / Partnerships
• MA
• Spin out
• Co-promotion
• . . . (permutations combinations of the above)

8
Biotech Partnering Deal Structures

• Deal structure dependant on limited by
• Partnering Objectives
• Market
• Therapeutic Market
• Disease indication
• Competitive products
• Product differentiation
• Partnering Market
• Potential partners
• Competitive products
• Product differentiation
• Creativity

9
Biotech Partnering Tips for Success

• Choosing Your Partner
• Preparation
• Closing the Deal
• Relationship Maintenance

10
Forum On Financing Biotechs Partnering
BC Biotech

• The Biotech Perspective
• May 15, 2002
• Celia Courchene
• VP, Business Development
• Xenon Genetics Inc.